Abiraterone (Zytiga®) approved in the EU for treatment of metastatic castration-resistant prostate cancer prior to chemotherapy
Source: BioSpace
Area: News
According to BioSpace, the European Commission (EC) has approved an extension to the license of abiraterone to include its use, in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. Abiraterone has until now has been approved only for use in men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
The approval follows a...
Source: NeLM - News - January 14, 2013 Category: Drugs & Pharmacology Source Type: news
RCT: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer - results from the GETUG-AFU 15 study
Source: Lancet Oncology
Area: News
According to a study published early online in the Lancet Oncology, docetaxel should not be used as part of first-line treatment for patients with non-castrate metastatic prostate cancer.
Researchers conducted the phase III study to investigate the effects of the addition of docetaxel to androgen-deprivation therapy (ADT) for patients with metastatic non-castrate prostate cancer. The phase III open-label study involved 385 patients aged over 18 years and with histologically confirmed adenocarcinoma of the prostate and radiologically proven metastatic disease, a Karnofsky score...
Source: NeLM - News - January 8, 2013 Category: Drugs & Pharmacology Source Type: news
Phase III study of 2-weekly versus 3-weekly docetaxel for castration-resistant advanced prostate cancer
Source: Lancet Oncology
Area: News
According to the results of a Phase III study published early online in The Lancet Oncology, a 2-weekly docetaxel regimen was well tolerated and improved time to treatment failure compared with the standard 3-weekly regimen in men with hormone-refractory prostate cancer.
The authors note that androgen deprivation is a standard treatment for advanced prostate cancer; it is not however curative and most patients develop castration-resistant disease within a median of 2 years. Several treatment options are available for patients with hormone-refractory prostate cancer, including...
Source: NeLM - News - January 7, 2013 Category: Drugs & Pharmacology Source Type: news
New Treatment Options Featured in NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines
JENKINTOWN, PA — The National Comprehensive Cancer Network (NCCN), an alliance of nineteen of the world’s leading cancer centers, announces that the NCCN Non-Small Cell Lung Cancer Guideline has recently been updated to broaden the options for treatment of advanced disease. NCCN’s panel of oncology experts added pemetrexed (Alimta, Eli Lilly and Company) as an option for second-line therapy for lung cancer. The panel indicated that it has been shown to be equivalent to docetaxel (Taxotere, San... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 28, 2005 Category: Cancer & Oncology Source Type: news
